CY1124032T1 - Παραγωγα 3-μεθυλο-πυρρολιδινο-2,5-διονης χρησιμα ως ανταγωνιστες του υποδοχεα cgrp - Google Patents
Παραγωγα 3-μεθυλο-πυρρολιδινο-2,5-διονης χρησιμα ως ανταγωνιστες του υποδοχεα cgrpInfo
- Publication number
- CY1124032T1 CY1124032T1 CY20211100293T CY211100293T CY1124032T1 CY 1124032 T1 CY1124032 T1 CY 1124032T1 CY 20211100293 T CY20211100293 T CY 20211100293T CY 211100293 T CY211100293 T CY 211100293T CY 1124032 T1 CY1124032 T1 CY 1124032T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pyrrolidine
- methyl
- cgrp receptor
- receptor antagonists
- dione derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει μια ένωση με Τύπο II ή ένα φαρμακευτικά αποδεκτό άλας ή ένυδρο άλας αυτής, που είναι χρήσιμη ως ανταγωνιστής του υποδοχέα CGRP.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762506204P | 2017-05-15 | 2017-05-15 | |
PCT/US2018/031526 WO2018213059A1 (en) | 2017-05-15 | 2018-05-08 | 3-methyl-pyrrolidine-2,5-dione derivatives useful as cgrp receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124032T1 true CY1124032T1 (el) | 2022-05-27 |
Family
ID=62245454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100293T CY1124032T1 (el) | 2017-05-15 | 2021-04-06 | Παραγωγα 3-μεθυλο-πυρρολιδινο-2,5-διονης χρησιμα ως ανταγωνιστες του υποδοχεα cgrp |
Country Status (18)
Country | Link |
---|---|
US (1) | US10336726B2 (el) |
EP (1) | EP3625221B1 (el) |
JP (1) | JP6794583B2 (el) |
CN (1) | CN110662741B (el) |
AR (1) | AR111665A1 (el) |
CA (1) | CA3061762C (el) |
CY (1) | CY1124032T1 (el) |
DK (1) | DK3625221T3 (el) |
ES (1) | ES2870325T3 (el) |
HR (1) | HRP20210655T1 (el) |
HU (1) | HUE054448T2 (el) |
LT (1) | LT3625221T (el) |
PL (1) | PL3625221T3 (el) |
PT (1) | PT3625221T (el) |
RS (1) | RS61657B1 (el) |
SI (1) | SI3625221T1 (el) |
TW (1) | TW201904955A (el) |
WO (1) | WO2018213059A1 (el) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11066386B2 (en) | 2017-05-15 | 2021-07-20 | Eli Lilly And Company | CGRP receptor antagonists |
CN114746409A (zh) * | 2019-12-12 | 2022-07-12 | 伊莱利利公司 | 可用作正电子发射断层扫描术的示踪剂化合物的cgrp拮抗剂 |
CN115704811B (zh) * | 2022-12-26 | 2023-03-31 | 南京威凯尔生物医药科技有限公司 | 一种高效液相色谱法检测乌布吉泮及其对映体和非对映体杂质的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6680387B2 (en) | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
US9227972B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam CGRP receptor antagonists |
TW201718574A (zh) | 2015-08-12 | 2017-06-01 | 美國禮來大藥廠 | Cgrp受體拮抗劑 |
TWI636041B (zh) | 2015-08-12 | 2018-09-21 | 美國禮來大藥廠 | Cgrp受體拮抗劑 |
-
2018
- 2018-05-02 AR ARP180101138A patent/AR111665A1/es unknown
- 2018-05-02 TW TW107114809A patent/TW201904955A/zh unknown
- 2018-05-08 DK DK18727529.2T patent/DK3625221T3/da active
- 2018-05-08 JP JP2020512768A patent/JP6794583B2/ja not_active Expired - Fee Related
- 2018-05-08 PT PT187275292T patent/PT3625221T/pt unknown
- 2018-05-08 HU HUE18727529A patent/HUE054448T2/hu unknown
- 2018-05-08 CA CA3061762A patent/CA3061762C/en active Active
- 2018-05-08 EP EP18727529.2A patent/EP3625221B1/en active Active
- 2018-05-08 US US15/973,681 patent/US10336726B2/en not_active Expired - Fee Related
- 2018-05-08 WO PCT/US2018/031526 patent/WO2018213059A1/en unknown
- 2018-05-08 LT LTEP18727529.2T patent/LT3625221T/lt unknown
- 2018-05-08 PL PL18727529T patent/PL3625221T3/pl unknown
- 2018-05-08 RS RS20210400A patent/RS61657B1/sr unknown
- 2018-05-08 CN CN201880032549.5A patent/CN110662741B/zh not_active Expired - Fee Related
- 2018-05-08 SI SI201830241T patent/SI3625221T1/sl unknown
- 2018-05-08 ES ES18727529T patent/ES2870325T3/es active Active
-
2021
- 2021-04-06 CY CY20211100293T patent/CY1124032T1/el unknown
- 2021-04-26 HR HRP20210655TT patent/HRP20210655T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018213059A1 (en) | 2018-11-22 |
CA3061762A1 (en) | 2018-11-22 |
AR111665A1 (es) | 2019-08-07 |
DK3625221T3 (da) | 2021-04-19 |
SI3625221T1 (sl) | 2021-04-30 |
PL3625221T3 (pl) | 2021-08-23 |
PT3625221T (pt) | 2021-04-15 |
US10336726B2 (en) | 2019-07-02 |
JP6794583B2 (ja) | 2020-12-02 |
CN110662741B (zh) | 2022-08-16 |
RS61657B1 (sr) | 2021-04-29 |
US20180327384A1 (en) | 2018-11-15 |
TW201904955A (zh) | 2019-02-01 |
LT3625221T (lt) | 2021-04-26 |
CA3061762C (en) | 2021-11-09 |
EP3625221B1 (en) | 2021-03-03 |
ES2870325T3 (es) | 2021-10-26 |
CN110662741A (zh) | 2020-01-07 |
HRP20210655T1 (hr) | 2021-05-28 |
EP3625221A1 (en) | 2020-03-25 |
JP2020519686A (ja) | 2020-07-02 |
HUE054448T2 (hu) | 2021-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124863T1 (el) | Οξεα τριαζολ-ν-συνδεδεμενου καρβαμοϋλ-κυκλοεξυλιου ως ανταγωνιστες lpa | |
CY1123443T1 (el) | Οξεα καρβαμοϋλοξυμεθυλ-τριαζολ-κυκλοεξυλιου ως ανταγωνιστες lpa | |
CY1124032T1 (el) | Παραγωγα 3-μεθυλο-πυρρολιδινο-2,5-διονης χρησιμα ως ανταγωνιστες του υποδοχεα cgrp | |
CY1125110T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
CY1120705T1 (el) | Καινοφανεις αναστολεις αποακετυλασων ιστονων | |
EA201891615A1 (ru) | Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора | |
CY1122182T1 (el) | Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες | |
CY1120089T1 (el) | Παραγωγα ουριας ή φαρμακολογικως αποδεκτα αλατα εξ' αυτων χρησιμα ως αγωνιστες του παρομοιου με υποδοχεα πεπτιδιου φορμυλιου 1(fprl-1) | |
CY1124059T1 (el) | Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa | |
CY1122196T1 (el) | Παραγωγα πυραζολοπυριμιδονης ή πυρρολοτριαζονης, μεθοδος παρασκευης αυτων και φαρμακευτικες εφαρμογες αυτων | |
EA202091500A1 (ru) | Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa | |
EA201890156A1 (ru) | Антагонисты рецептора cgrp | |
EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
CY1123592T1 (el) | Αναστολεας κινασης aurora a | |
DK3672951T3 (da) | Quinoxalinderivater som adenosinreceptorantagonister | |
CL2017001831A1 (es) | Derivados de hidroxialquil–piperazina como moduladores del receptor cxcr3 | |
CY1121693T1 (el) | Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1 | |
CY1121401T1 (el) | Ενωση φαινυλο-τετραϋδροϊσοκινολινης υποκατεστημενη με ετεροαρυλ | |
CY1122321T1 (el) | Παραγωγα φθοροϊνδολιου ως θετικοι αλλοστερικοι διαμορφωτες του μουσκαρινικου υποδοχεα μ1 | |
CY1123406T1 (el) | Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας | |
DK3914600T3 (da) | Thiazolopyridinderivater som adenosinreceptorantagonister | |
CY1123185T1 (el) | Παραγωγα ινδολιου | |
EA201892370A1 (ru) | Замещенные конденсированные пиримидиноновые соединения | |
DK3870582T3 (da) | 5-azaindazolderivater som adenosinreceptorantagonister |